Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a ...
The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...
Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read why AMGN stock is a Buy.
Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...
Shares of the company began plunging in November, but its overall strength should set the stock up for some serious potential gains in 2025.
Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators have placed a ...
AbbVie is a resurging Dividend King. Amgen's recent clinical setback makes its stock available at a discount. Gilead Sciences ...
Amgen’s mysterious obesity asset will remain a mystery for a bit longer—the FDA has put the candidate’s phase 1 trial on a clinical hold, the company announced Feb. 4. Amgen has not detailed ...
MariTide Phase 3 studies to begin in first half of year FDA places hold on AMG 513 obesity drug trial Amgen's Q4 earnings beat estimates, revenue up 11% Feb 4 (Reuters) - Amgen (AMGN.O), opens new ...
(Reuters) - Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug candidate MariTide will start before mid-year but regulators ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback